Verrica pharmaceuticals inc. (VRCA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities
Net loss

0

-

-

-

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

3,551

3,333

3,185

2,963

2,896

2,251

0

0

0

Accretion of discounts on marketable securities

797

1,063

0

0

0

-

-

-

-

Depreciation expense

67

64

0

0

0

-

-

-

-

Non cash interest expense

0

-

-

-

-

-

-

-

-

Reduction in operating lease right-of-use asset

230

193

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

874

1,621

1,246

-470

-31

923

0

0

0

Other receivable - related party

-

-

-

-

0

-

-

-

-

Accounts payable

-34

263

-56

229

527

769

0

0

0

Accrued expenses and other current liabilities

0

-

-

-

0

-

-

-

-

Accrued expenses

-

-

-

-

-

1,068

0

0

0

Accounts payable and accrued expenses - related party

-

-

-

-

0

-

-

-

-

Accounts payable and accrued expenses - related party

-

-

-

-

-

-

-

0

0

Operating lease liability

-123

-119

0

0

0

-

-

-

-

Net cash used in operating activities

-28,397

-27,408

-26,098

-24,007

-22,637

-17,874

0

0

0

Cash flows from investing activities
Sales and maturities of marketable securities

99,705

117,715

0

0

0

-

-

-

-

Purchases of marketable securities

73,941

89,854

0

0

0

-

-

-

-

Purchases of property and equipment

0

-

-

-

-

774

0

0

0

Net cash provided by investing activities

23,159

25,955

-1,841

-58,450

-58,807

-79,894

0

0

0

Cash flows from financing activities
Proceeds from exercise of stock options

427

423

0

0

0

-

-

-

-

Proceeds from issuance of debt, net

0

-

-

-

-

-

-

-

-

Repayment of subscription receivable

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

35,297

423

228

-840

78,386

99,376

0

0

0

Net increase in cash and cash equivalents

0

-

-

-

0

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

0

0

Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases payable or accrued at period end

0

-

0

0

0

-

-

0

0

Debt discount costs included in accrued expense at period end

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

0

Series C Convertible Preferred Stock [Member]
Payment of stock issuance costs

-

-

-

-

-

-

-

0

0

Proceeds received from subscription receivable / issuance of preferred stock

-

-

-

-

-

21,000

0

0

0